References
- NORDCAN [Internet]. Copenhagen (Denmark): Association of the Nordic Cancer Registries; c2009. Data from the online tool in the NORDCAN database containing prevalence data [updated 2018 June 28; cited 2019 Jul 10]. Available from: http://www-dep.iarc.fr/nordcan/english/frame.asp.
- Cornford P, Bellmunt J, Bolla M, et al. EAU-ESTRO-SIOG guidelines on prostate cancer. Part II: treatment of relapsing, metastatic, and castration-resistant prostate cancer. Eur Urol. 2017;71:630–642.
- Franck Lissbrant I, Ventimiglia E, Robinson D, et al. Nationwide population-based study on the use of novel antiandrogens in men with prostate cancer in Sweden. Scand J Urol. 2018;52:143–150.
- eMC [Internet]. Surrey (United Kingdom): Datapharm Ltd; c2019. Xtandi 40mg soft capsules; [updated 2018 Oct 30; cited 2019 Jul 10]. Available from: https://www.medicines.org.uk/emc/product/3203/smpc.
- Scher HI, Fizazi K, Saad F, et al. Increased survival with enzalutamide in prostate cancer after chemotherapy. N Engl J Med. 2012;367:1187–1197.
- Beer TM, Armstrong AJ, Rathkopf DE, et al. Enzalutamide in metastatic prostate cancer before chemotherapy. N Engl J Med. 2014;371:424–433.
- Garrison LP Jr., Neumann PJ, Erickson P, et al. Using real-world data for coverage and payment decisions: the ISPOR Real-World Data Task Force report. Value Health. 2007;10:326–335.
- Blommestein HM, Franken MG, Uyl-de Groot CA. A practical guide for using registry data to inform decisions about the cost effectiveness of new cancer drugs: lessons learned from the PHAROS registry. Pharmacoeconomics. 2015;33:551–560.
- Mottet N, Bellmunt J, Briers E, et al. EAU - ESTRO - ESUR - SIOG Guidelines on prostate cancer [Internet]. The Netherlands: European Association of Urology; [cited 2018 Jun]. Available from: http://uroweb.org/guideline/prostate-cancer/.
- Blonde L, Khunti K, Harris SB, et al. Interpretation and impact of real-world clinical data for the practicing clinician. Adv Ther. 2018;35:1763–1774.
- The Dental and Pharmaceutical Benefits Agency [Internet]. Stockholm (Sweden): Tandvårds- och läkemedelsförmånsverket; Xtandi ingår i högkostnadsskyddet [Xtandi is included in the high-cost protection]; [cited 2019 Jul 10]. Available from: https://www.tlv.se/beslut/beslut-lakemedel/generell-subvention/arkiv/2015-06-15-xtandi-ingar-i-hogkostnadsskyddet.html.
- Jellvert A, Lissbrant IF, Edgren M, et al. Effective oral combination metronomic chemotherapy with low toxicity for the management of castration-resistant prostate cancer. Exp Ther Med. 2011;2:579–584.
- Booth CM, Tannock IF. Randomised controlled trials and population-based observational research: partners in the evolution of medical evidence. Br J Cancer. 2014;110:551–555.
- ClinicalTrials.gov [Internet]. A safety and efficacy study of oral MDV3100 in chemotherapy-naive patients with progressive metastatic prostate cancer (PREVAIL); [cited 2019 Jul 10]. Available from: https://clinicaltrials.gov/ct2/show/NCT01212991.
- ClinicalTrials.gov [Internet]. Safety and efficacy study of MDV3100 in patients with castration-resistant prostate cancer who have been previously treated with docetaxel-based chemotherapy (AFFIRM); [cited 2019 Jul 10]. Available from: https://clinicaltrials.gov/ct2/show/NCT01212991.
- Handbook for visiting students [Internet]. Lund (Sweden): Lund University; 2016. [cited 2019 Jul 10]. Available from: https://issuu.com/medfak-lu/docs/handbook_for_visiting_students_issu.
- Region Skåne [Internet]. Kristianstad (Sweden): Region Skåne; c2018. Positiv utveckling för prostatapatienter [Positive development for prostate patients]; [cited 2019 Jul 10]. Available from: https://www.skane.se/organisation-politik/Nyheter/Halsa-och-vard/2017/positiv-utveckling-for-prostatapatienter/.
- Uppsala: Regionala Cancercentrum I Samverkan; Nationellt vårdprogram för prostatacancer [Internet]. Prostatacancer: Nationellt vårdprogram [Prostate Cancer: National Care Program]: version 1.2. Available from: https://www.cancercentrum.se/samverkan/cancerdiagnoser/prostata/vardprogram/.